Now that the first study sites have been initiated, we can start collecting clinical data. Data on the use of cangrelor in high-risk patients with acute myocardial infarction and PCI who have experienced CPR, cardiogenic shock or received mechanical or non-invasive ventilation will be collected from pre-existing clinical documentation and systematically analyzed. The register trial has also been extended to include clinical trial sites in Austria in order to be able to generate a significant number of patient outcomes. The goal is to generate clinical data from approximately 450 consecutive patients within the next six months.
